BioSpace News Archive

Daiichi Sankyo Company, Limited and AstraZeneca have received notification of acceptance by the U.S. Food and Drug Administration of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the U.S. with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen.

Ascletis Pharma Inc. announces the Investigational New Drug application approval by U.S. Food and Drug Administration and initiation of global development of ASC22, a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B.

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301.

Immuron Limited is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.

Digbi Health today announced incorporating ethnic-specific risk scores for nutrition, fitness, obesity, diabetes, hypertension, mental and digestive health across its virtual care program for people living with polychronic physical and mental illness associated with inflammatory gut and weight.

Stallergenes Greer today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

Evelo Biosciences, Inc. today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis.

ASSA ABLOY has entered into an agreement to acquire Vigil Health Solutions Inc. (“Vigil”), a leader in innovative call systems and resident monitoring solutions for senior living.

Today, SparX announced that the FDA has approved their IND application for its organically developed anti-claudin18.2 antibody, SPX-101.

Boundless Bio today announced that Peter Krein has been appointed as Vice President of Precision Medicine.